Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash & Current Investments (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Cash & Current Investments data on record, last reported at $242.0 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 38.35% year-over-year to $242.0 million; the TTM value through Sep 2025 reached $267.2 million, down 25.17%, while the annual FY2025 figure was $242.0 million, 38.35% down from the prior year.
  • Cash & Current Investments reached $242.0 million in Q4 2025 per PRAX's latest filing, down from $267.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $392.6 million in Q4 2024 and bottomed at $56.0 million in Q2 2022.
  • Average Cash & Current Investments over 4 years is $193.3 million, with a median of $165.9 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: soared 382.86% in 2024, then crashed 38.35% in 2025.
  • A 4-year view of Cash & Current Investments shows it stood at $61.6 million in 2022, then skyrocketed by 31.95% to $81.3 million in 2023, then skyrocketed by 382.86% to $392.6 million in 2024, then tumbled by 38.35% to $242.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $242.0 million in Q4 2025, $267.2 million in Q3 2025, and $301.3 million in Q2 2025.